24/01/20 -"Besides lowering our DCF and NAV, we have increased the discount on the peer-based valuations to factor in this disappointing news. Our target price resets c.14% lower."
Pages
52
Language
English
Published on
24/01/20
You may also be interested by these reports :
26/04/24
The Q1 profits surpassed the street’s expectations, as all the three key molecules witnessed decent growth. Segment-wise, Spain and International ...
26/04/24
Hikma’s qualitative Q1 commentary entailed a positive tone for all the segments. Moreover, the management reaffirmed the full-year guidance. Since ...
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...